• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

FDA approval marks new drug class for type 2 diabetes

Article

Canaglifozin (Invokana, Janssen Pharmaceuticals) tablets, recently approved by the U.S. Food and Drug Administration for the improvement of glycemic control in adults with type 2 diabetes, is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 inhibitors.

 

Canaglifozin (Invokana, Janssen Pharmaceuticals) tablets, recently approved by the U.S. Food and Drug Administration (FDA) for the improvement of glycemic control in adults with type 2 diabetes, is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. 

The drug blocks the reabsorption of glucose by the kidney, increases glucose excretion, and lowers blood glucose levels. Safety and effectiveness of canaglifozin were evaluated in nine clinical trials and showed improvement in hemoglobin A1c levels and fasting plasma glucose levels.

It has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies, such as insulin. The drug is not intended to treat type 1 diabetes.

Common side effects are vaginal yeast infection and urinary tract infection. Canaglifozin also can cause a reduction in intravascular volume, leading to orthostatic or postural hypotension, which may result in dizziness or fainting most common in the first 3 months of therapy. 

The FDA is requiring five postmarketing studies for canaglifozin: a cardiovascular outcomes trial, an enhanced pharmacovigilance program, a bone safety study, and two pediatric studies under the Pediatric Research Equity Act.

Janssen Pharmaceuticals; (800) 526-7736; www.janssenpharmaceuticalsinc.com/

Related Videos
Kyle Zebley headshot
Kyle Zebley headshot
Kyle Zebley headshot
Michael J. Barry, MD
Hadi Chaudhry, President and CEO, CareCloud
Claire Ernst, JD, gives expert advice
Arien Malec